Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Top Cited Papers
- 16 July 2015
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 373 (3), 232-242
- https://doi.org/10.1056/nejmoa1501352
Abstract
Data are lacking on the long-term effect on cardiovascular events of adding sitagliptin, a dipeptidyl peptidase 4 inhibitor, to usual care in patients with type 2 diabetes and cardiovascular disease. In this randomized, double-blind study, we assigned 14,671 patients to add either sitagliptin or placebo to their existing therapy. Open-label use of antihyperglycemic therapy was encouraged as required, aimed at reaching individually appropriate glycemic targets in all patients. To determine whether sitagliptin was noninferior to placebo, we used a relative risk of 1.3 as the marginal upper boundary. The primary cardiovascular outcome was a composite of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for unstable angina. During a median follow-up of 3.0 years, there was a small difference in glycated hemoglobin levels (least-squares mean difference for sitagliptin vs. placebo, −0.29 percentage points; 95% confidence interval [CI], −0.32 to −0.27). Overall, the primary outcome occurred in 839 patients in the sitagliptin group (11.4%; 4.06 per 100 person-years) and 851 patients in the placebo group (11.6%; 4.17 per 100 person-years). Sitagliptin was noninferior to placebo for the primary composite cardiovascular outcome (hazard ratio, 0.98; 95% CI, 0.88 to 1.09; P<0.001). Rates of hospitalization for heart failure did not differ between the two groups (hazard ratio, 1.00; 95% CI, 0.83 to 1.20; P=0.98). There were no significant between-group differences in rates of acute pancreatitis (P=0.07) or pancreatic cancer (P=0.32). Among patients with type 2 diabetes and established cardiovascular disease, adding sitagliptin to usual care did not appear to increase the risk of major adverse cardiovascular events, hospitalization for heart failure, or other adverse events. (Funded by Merck Sharp & Dohme; TECOS ClinicalTrials.gov number, NCT00790205.)Keywords
This publication has 15 references indexed in Scilit:
- Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled trialsThe Lancet Diabetes & Endocrinology, 2015
- In This Issue of Diabetes CareDiabetes Care, 2014
- Do Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Cause Heart Failure?Clinical Therapeutics, 2014
- Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetesThe Lancet, 2014
- Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes MellitusNew England Journal of Medicine, 2013
- Alogliptin after Acute Coronary Syndrome in Patients with Type 2 DiabetesNew England Journal of Medicine, 2013
- 10-Year Follow-up of Intensive Glucose Control in Type 2 DiabetesNew England Journal of Medicine, 2008
- Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular CausesNew England Journal of Medicine, 2007
- The role of gut hormones in glucose homeostasisJCI Insight, 2007
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)The Lancet, 1998